Revised forms for the submission of the Confidence-Building Measures

At the Third Review Conference it was agreed that all States Parties present the following declaration, later amended by the Seventh Review Conference:

Declaration form on Nothing to Declare or Nothing New to Declare for use in the information exchange

Measure	Nothing to declare	Nothing new to declare	Year of last declaration if nothing new to declare
A, part 1		**X**	**2021**
A, part 2 (i)		**X**	**2021**
A, part 2 (ii)		X	**2021**
A, part 2 (iii)		X	**2021**
B	X		
C	X		
E		X	**2021**
F		X	**2021**
G		X	**2021**

(Please mark the appropriate box(es) for each measure with a tick and fill in the year of last declaration in the last column where applicable.)

Date: _____**10/04/2023**_____

State Party to the Convention: ___**PORTUGAL**_____

Date of ratification/accession to the Convention: ___**15-05-1975**_____

National point of contact: **Eurico Rodrigues** (Head, Disarmament and Non-Proliferation Division, Ministry of Foreign Affairs), Phone +351 213 946 739, e-mail: eurico.rodrigues@mne.pt, dsd@mne.pt / **Marisa Nobre** (Disarmament and Non Proliferation Division, Ministry of Foreign Affairs), Phone +351 213 946 231, e-mail: marisa.nobre@mne.pt

Active promotion of contacts

The Third Review Conference agreed that States parties continue to implement the following:
"Active promotion of contacts between scientists, other experts and facilities engaged in biological research directly related to the Convention, including exchanges and visits for joint research on a mutually agreed basis."

In order to actively promote professional contacts between scientists, joint research projects and other activities aimed at preventing or reducing the occurrence of ambiguities, doubts and suspicions and at improving international cooperation in the field of peaceful bacteriological (biological) activities, the Seventh Review Conference encouraged States parties to share forward looking information, to the extent possible,

- on planned international conferences, seminars, symposia and similar events dealing with biological research directly related to the Convention, and

- on other opportunities for exchange of scientists, joint research or other measures to promote contacts between scientists engaged in biological research directly related to the Convention,

including through the Implementation Support Unit (ISU) within the United Nations Office for Disarmament Affairs.

Confidence-Building Measure "A"

Part 1 Exchange of data on research centres and laboratories

At the Third Review Conference it was agreed that States Parties continue to implement the following:

"Exchange of data, including name, location, scope and general description of activities, on research centres and laboratories that meet very high national or international safety standards established for handling, for permitted purposes, biological materials that pose a high individual and community risk or specialize in permitted biological activities directly related to the Convention."

Modalities

The Third Review Conference agreed on the following, later amended by the Seventh Review Conference:

Data should be provided by States Parties on each facility, within their territory or under their jurisdiction or control anywhere, which has any maximum containment laboratories meeting those criteria for such maximum containment laboratories as specified in the latest edition of the WHO[1] Laboratory Biosafety Manual and/or OIE[2] Terrestrial Manual or other equivalent guidelines adopted by relevant international organisations, such as those designated as biosafety level 4 (BL4, BSL4 or P4) or equivalent standards.

States Parties that do not possess a facility meeting criteria for such maximum containment should continue to Form A, part 1 (ii).

[1] World Health Organization
[2] World Organization for Animal Health

Form A, part 1 (i)

Exchange of data on research centres and laboratories[3]

1. Instituto Nacional de Saúde Doutor Ricardo Jorge. I.P. (Portuguese National Health Institute) - INSA

2. Instituto Nacional de Investigação Agrária e Veterinária, I.P, (Portuguese Institute for Animal Health Research)

3. Faculdade de Farmácia da Universidade de Lisboa (Faculty of Pharmacy, University of Lisbon)

4. Faculdade de Ciências da Universidade de Lisboa (Faculty of Ciences, University of Lisbon)

5. Laboratório de Bromatologia e Defesa Biológica do Exército Português (Defence Research)

6. Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa (Institute Of Chemical And Biological Technology – New University of Lisbon)

7. Autoridade Tributária e Aduaneira (AT) – Direção de Serviços de Licenciamento (DSL) / Ministério das Finanças (Tax and Customs Authority – Ministry of Finance)

8. Instituto de Higiene e Medicina Tropical – Universidade Nova de Lisboa (Hygiene and Tropical Medicine Institute – New University of Lisbon)

9. INFARMED - Autoridade Nacional do Medicamento e Produtos de Saúde, I.P. (National Authority of Medicines and Health Products, I.P.)

10. Escola de Medicina – Universidade do Minho (Medicine School – Minho University)

---

[3] The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.

1. INSTITUTO NACIONAL DE SAÚDE DOUTOR RICARDO JORGE, I.P. (PORTUGUESE NATIONAL INSTITUTE OF HEALTH DOUTOR RICARDO JORGE) – (INSA)

Form A, part 1 (i)

1.	Name(s) of facility[4]	**Departamento de Doenças Infecciosas**
2.	Responsible public or private organization or company	**Public** **National Institute of Health Doutor Ricardo Jorge**
3.	Location and postal address	**Avenida Padre Cruz, 1649-016, Lisbon**

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

Ministry of Health.

5. Number of maximum containment units[5] within the research centre and/or laboratory, with an indication of their respective size (m^2)

5BSL3: 2 in Lisbon (100m2, aprox.); 2 in Águas de Moura (40m2 + 40m2); 1 in Porto (100m2).

6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

Research, diagnostic activities and animal/ vector manipulations involving group risk 3 microorganisms.

[4] For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".

[5] In accordance with the latest edition of the WHO Laboratory Biosafety Manual, or equivalent.

Form A, part 1 (ii)

If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents[6] on a State Party's territory:

Biosafety level 3[7]	**Yes**
Biosafety level 2[8] (if applicable)	**Yes**

Any additional relevant information as appropriate:

_____

_____

_____

Part 2 Exchange of information on national biological defence research and development programmes

At the Third Review Conference it was agreed that States Parties are to implement the following:

In the interest of increasing the transparency of national research and development programmes on biological defence, the States Parties will declare whether or not they conduct such programmes. States Parties agreed to provide, annually, detailed information on their biological defence research and development programmes including summaries of the objectives and costs of effort performed by contractors and in other facilities. If no biological defence research and development programme is being conducted, a null report will be provided.

States Parties will make declarations in accordance with the attached forms, which require the following information:

(1) The objective and summary of the research and development activities under way indicating whether work is conducted in the following areas: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research;

[6] Microorganisms pathogenic to humans and/or animals

[7] In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

[8] In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

(2) Whether contractor or other non-defence facilities are utilized and the total funding provided to that portion of the programme;

(3) The organizational structure of the programme and its reporting relationships; and

(4) The following information concerning the defence and other governmental facilities in which the biological defence research and development programme is concentrated;

(a) location;

(b) the floor areas (sqM) of the facilities including that dedicated to each of BL2, BL3 and BL4 level laboratories;

(c) the total number of staff employed, including those contracted full time for more than six months;

(d) numbers of staff reported in (c) by the following categories: civilian, military, scientists, technicians, engineers, support and administrative staff;

(e) a list of the scientific disciplines of the scientific/engineering staff;

(f) the source and funding levels in the following three areas: research, development, and test and evaluation; and

(g) the policy regarding publication and a list of publicly-available papers and reports.

Form A, part 2 (i)

National biological defence research and development programmes Declaration

Are there any national programmes to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such programmes would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

Yes/No

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of each programme.

Form A, part 2 (ii)

National biological defence research and development programmes

Description

1. State the objectives and funding of each programme and summarize the principal research and development activities conducted in the programme. Areas to be addressed shall include: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

2. State the total funding for each programme and its source.

3. Are aspects of these programmes conducted under contract with industry, academic institutions, or in other non-defence facilities?

No

4. If yes, what proportion of the total funds for each programme is expended in these contracted or other facilities?

5. Summarize the objectives and research areas of each programme performed by contractors and in other facilities with the funds identified under paragraph 4.

6. Provide a diagram of the organizational structure of each programme and the reporting relationships (include individual facilities participating in the programme).

7. Provide a declaration in accordance with Form A, part 2 (iii) for each facility, both governmental and non-governmental, which has a substantial proportion of its resources devoted to each national biological defence research and development programme, within the territory of the reporting State, or under its jurisdiction or control anywhere.

---

2. INSTITUTO NACIONAL DE INVESTIGAÇÃO AGRÁRIA E VETERINÁRIA, I.P. (R&D STATE LABORATORY OF THE MINISTRY OF AGRICULTURE) – (INIAV)

Form A, part 1 (i)

Exchange of data on research centres and laboratories[9]

1.	Name(s) of facility[10]	**Instituto Nacional de Investigação Agrária e Veterinária, I.P. / Unit of Animal Health**
2.	Responsible public or private organization or company	**R&D State Laboratory of Agriculture and Food Ministry INIAV, I.P.**
3.	Location and postal address	**Oeiras – Avenida da República, Quinta do Marquês, 2784-505; and Vila do Conde, Vairão – Rua dos Lagidos 4485-655.**

[9] The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.

[10] For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

All activities are supported by the Ministry of Agriculture and by Ministry of Finance. Some R&D activities are supported by the Foundation for Science and Technology (Ministry of Science Technology and Higher Education).

5. Number of maximum containment units[11] within the research centre and/or laboratory, with an indication of their respective size (m^2)

No (none) BSL4- laboratories

6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

The Instituto Nacional de Investigação Agrária e Veterinária, I.P. is a R&D State Laboratory of Ministry of Agriculture and Food, locaded in Oeiras (near Lisbon) and Vairão (Vila do Conde). The Laboratory's main activities are:

☐Laboratory diagnosis of animal diseases, including zoonoses.

☐ Performing R&D projects on diagnosis and epidemiology of animal diseases, including zoonoses.

Form A, part 1 (ii)

If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents[12] on a State Party's territory:

Biosafety level 3[13]	**Yes**
Biosafety level 2[14] (if applicable)	**Yes**

Any additional relevant information as appropriate:

• 1 Unit (68 m2) BSL 3 facility for TSE diseases, in Oeiras

• 1 Unit (100m2) BSL3 Brucella and Mycobacterium, in Oeiras

• 1 Unit (65 m2) BSL 3 for rabies, Avian influenza, and other viruses like Foot and Mouth disease and SARS-CoV-2 (SINCE JUL/2020)

[11] In accordance with the latest edition of the WHO Laboratory Biosafety Manual, or equivalent.
[12] Microorganisms pathogenic to humans and/or animals
[13] In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.
[14] In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

• A total of 2000 m2 BSL2 for Veterinary Virology, Bacteriology, Parasitology and Pathology, including rooms for veterinary necropsy at the headquarters building in Oeiras near Lisbon (Portugal)

• 1 Unit (100m2) BSL 3 Brucella, in Vairão, Vila do Conde

• A total of 2300 m2 BSL2 for Food and feed Microbiology, Veterinary Bacteriology and Pathology, including rooms for veterinary necropsy at Vairão's pole in Vila do Conde (North of Portugal).

Part 2 Exchange of information on national biological defence research and development programmes

At the Third Review Conference it was agreed that States Parties are to implement the following:

In the interest of increasing the transparency of national research and development programmes on biological defence, the States Parties will declare whether or not they conduct such programmes. States Parties agreed to provide, annually, detailed information on their biological defence research and development programmes including summaries of the objectives and costs of effort performed by contractors and in other facilities. If no biological defence research and development programme is being conducted, a null report will be provided.

States Parties will make declarations in accordance with the attached forms, which require the following information:

(1) The objective and summary of the research and development activities under way indicating whether work is conducted in the following areas: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research;

(2) Whether contractor or other non-defence facilities are utilized and the total funding provided to that portion of the programme;

(3) The organizational structure of the programme and its reporting relationships; and

(4) The following information concerning the defence and other governmental facilities in which the biological defence research and development programme is concentrated;

(a) location;

(b) the floor areas (sqM) of the facilities including that dedicated to each of BL2, BL3 and BL4 level laboratories;

(c) the total number of staff employed, including those contracted full time for more than six months;

(d) numbers of staff reported in (c) by the following categories: civilian, military, scientists, technicians, engineers, support and administrative staff;

(e) a list of the scientific disciplines of the scientific/engineering staff;

(f) the source and funding levels in the following three areas: research, development, and test and evaluation; and

(g) the policy regarding publication and a list of publicly-available papers and reports.

Form A, part 2 (i)

National biological defence research and development programmes Declaration

Are there any national programmes to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such programmes would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

No

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of each programme.

Confidence-Building Measure "F"

Declaration of past activities in offensive and/or defensive biological research and development programmes

In the interest of increasing transparency and openness, States parties shall declare whether or not they conducted any offensive and/or defensive biological research and development programmes since 1 January 1946.

If so, States parties shall provide information on such programmes, in accordance with Form F.

Form F

Declaration of past activities in offensive and/or defensive biological research and development programmes

1. Date of entry into force of the Convention for the State Party.

2. Past offensive biological research and development programmes:

No

- Period(s) of activities

- Summary of the research and development activities indicating whether work was performed concerning production, test and evaluation, weaponization, stockpiling of biological agents, the destruction programme of such agents and weapons, and other related research.

3. Past defensive biological research and development programmes:

No

- Period(s) of activities

- Summary of the research and development activities indicating whether or not work

was conducted in the following areas: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination, and other related research, with location if possible.

Confidence-Building Measure "G"

Declaration of vaccine production facilities

To further increase the transparency of biological research and development related to the Convention and to broaden scientific and technical knowledge as agreed in Article X, each State party will declare all facilities, both governmental and non-governmental, within its territory or under its jurisdiction or control anywhere, producing vaccines licensed by the State party for the protection of humans. Information shall be provided on Form G attached.

Form G

Declaration of vaccine production facilities

1. Name of facility:

   No

2. Location (mailing address):

   No

3. General description of the types of diseases covered:

   No

---

3. FACULDADE DE FARMÁCIA DA UNIVERSIDADE DE LISBOA (FACULTY OF PHARMACY, UNIVERSITY OF LISBON) – Departamento de Farmácia, Farmacologia e Tecnologias da Saúde

Form A, part 1 (i)

Exchange of data on research centres and laboratories[15]

1.	Name(s) of facility[16]	**Departamento de Farmácia, Farmacologia e Tecnologias da Saúde**
2.	Responsible public or private organization or company	**Faculdade de Farmácia da Universidade de Lisboa - Public**
3.	Location and postal address	**Avenida Professor Gama Pinto S/N 1649-003 Lisboa - PT**

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

5. Number of maximum containment units[17] within the research centre and/or laboratory, with an indication of their respective size (m^2)

6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

Form A, part 1 (ii)

If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents[18] on a State Party's territory:

Biosafety level 3[19]	**Yes**
Biosafety level 2[20] (if applicable)	**Yes**

[15] The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.

[16] For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".

[17] In accordance with the latest edition of the WHO Laboratory Biosafety Manual, or equivalent.

[18] Microorganisms pathogenic to humans and/or animals

[19] In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

[20] In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

Any additional relevant information as appropriate:

- **One BSL-3 Laboratory with 45m2**

- One BSL-2 Laboratory with 20m2

- Two Laboratories with 10m2

---

4. FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DE LISBOA (FACULTY OF CIENCES, UNIVERSITY OF LISBON)

Form A, part 1 (i)

Exchange of data on research centres and laboratories[21]

1.	Name(s) of facility[22]	**Faculdade de Ciências da Universidade de Lisboa (FCUL)**
2.	Responsible public or private organization or company	**Faculdade de Ciências da Universidade de Lisbon - Public**
3.	Location and postal address	**Campo Grande 1749-016, Lisbon**

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

R&D activity is supported by the Foundation for Science and Technology (Ministry of Education and Science), EU Framework Programmes and Structural Funds, private entities and industry

5. Number of maximum containment units[23] within the research centre and/or laboratory, with an indication of their respective size (m^2)

No (none) BSL-4 Laboratories

6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

Several R&D projects on antimicrobial resistance, pathogenicity, public health, biomonitorization, toxicology, ecotoxicology, pests and diseases control. Manipulation of biological samples, bacteria and viral agents classified as BS2 and 3 Level.

---

[21] The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.

[22] For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".

[23] In accordance with the latest edition of the WHO Laboratory Biosafety Manual, or equivalent.

Form A, part 1 (ii)

If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents[24] on a State Party's territory:

Biosafety level 3[25]	**Yes**
Biosafety level 2[26] (if applicable)	**Yes**

Any additional relevant information as appropriate:

BSL3 – Laboratory Center. This facility is new and started operating in May 2020.

BSL2 – Several laboratory investigations projects.

---

5. LABORATÓRIO DE BROMATOLOGIA E DEFESA BIOLÓGICA (DEFENCE RESEARCH)

Form A, part 1 (ii)

If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents[27] on a State Party's territory:

[24] Microorganisms pathogenic to humans and/or animals

[25] In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

[26] In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

[27] Microorganisms pathogenic to humans and/or animals

Biosafety level 3[28]	**Yes**
Biosafety level 2[29] (if applicable)	**Yes**

Any additional relevant information as appropriate:

_____

_____

_____

_____

Part 2 Exchange of information on national biological defence research and development programmes

At the Third Review Conference it was agreed that States Parties are to implement the following:

In the interest of increasing the transparency of national research and development programmes on biological defence, the States Parties will declare whether or not they conduct such programmes. States Parties agreed to provide, annually, detailed information on their biological defence research and development programmes including summaries of the objectives and costs of effort performed by contractors and in other facilities. If no biological defence research and development programme is being conducted, a null report will be provided.

States Parties will make declarations in accordance with the attached forms, which require the following information:

(1) The objective and summary of the research and development activities under way indicating whether work is conducted in the following areas: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research;

(2) Whether contractor or other non-defence facilities are utilized, and the total funding provided to that portion of the programme;

(3) The organizational structure of the programme and its reporting relationships; and

(4) The following information concerning the defence and other governmental facilities in which the biological defence research and development programme is concentrated;

[28] In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

[29] In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

(a) location;

(b) the floor areas (sqM) of the facilities including that dedicated to each of BL2, BL3 and BL4 level laboratories;

(c) the total number of staff employed, including those contracted full time for more than six months;

(d) numbers of staff reported in (c) by the following categories: civilian, military, scientists, technicians, engineers, support and administrative staff;

(e) a list of the scientific disciplines of the scientific/engineering staff;

(f) the source and funding levels in the following three areas: research, development, and test and evaluation; and

(g) the policy regarding publication and a list of publicly-available papers and reports.

Form A, part 2 (i)

National biological defence research and development programmes Declaration

Are there any national programmes to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such programmes would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

Yes

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of each programme.

Form A, part 2 (ii)

National biological defence research and development programmes

Description

1. State the objectives and funding of each programme and summarize the principal research and development activities conducted in the programme. Areas to be addressed shall include: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

Physical protection / decontamination: CBRN suits development, decontamination of Airplanes.
Diagnostic techniques: detection of microorganisms with MALDI-TOF technology.
Other related research: Pre-standardization related with electronic chain of custody in biological samples.

2.State the total funding for each programme and its source.

Physical protection / decontamination: 80.000 € - European funds
Diagnostic techniques: 18.000€ - National funds
Other related research: 70.000€ - European funds

3. Are aspects of these programmes conducted under contract with industry, academic institutions, or in other non-defence facilities?

No

4. If yes, what proportion of the total funds for each programme is expended in these contracted or other facilities?

5. Summarize the objectives and research areas of each programme performed by contractors and in other facilities with the funds identified under paragraph 4.

6. Provide a diagram of the organizational structure of each programme and the reporting relationships (include individual facilities participating in the programme).

7. Provide a declaration in accordance with Form A, part 2 (iii) for each facility, both governmental and non-governmental, which has a substantial proportion of its resources devoted to each national biological defence research and development programme, within the territory of the reporting State, or under its jurisdiction or control anywhere.

Form A, part 2 (iii)

National biological defence research and development programmes

Facilities

Complete a form for each facility declared in accordance with paragraph 7 in Form A, part 2 (ii).

In shared facilities, provide the following information for the biological defence research and development portion only.

1. What is the name of the facility?

Laboratório de Bromatologia e Defesa Biológica.

2. Where is it located (include both address and geographical location)?

Avenida Alfredo Bensaúde, 1849 – 012 Lisboa.

3. Floor area of laboratory areas by containment level:

BL2 **30 sqM**

BL3 **51 sqM**

BL4 n.a.

Total laboratory floor area 81 **sqM**

4. The organizational structure of each facility.

(i) Total number of personnel **_15**_____

(ii) Division of personnel:

Military **_13**_____

Civilian **_2**_____

(iii) Division of personnel by category:

Scientists 10_____

Engineers **_0**_____

Technicians **_3**_____

Administrative and support staff **_2**_____

(iv) List the scientific disciplines represented in the scientific/engineering staff.

Veterinary medicine, molecular biology, microbiology, parasitology, infectiology, and food science.

(v) Are contractor staff working in the facility? If so, provide an approximate number.

No

(vi) What is (are) the source(s) of funding for the work conducted in the facility, including indication if activity is wholly or partly financed by the Ministry of Defence?

Ministry of Defence funding and research programmes co-funded by national and international programmes.

(vii) What are the funding levels for the following programme areas:

Research **_40%**_____

Development **_10%**_____

Test and evaluation **_50%**_____

(viii) Briefly describe the publication policy of the facility:
Publication in national and international scientific journals, presentations in scientific congress and seminars.

(ix) Provide a list of publicly-available papers and reports resulting from the work published during the previous 12 months. (To include authors, titles and full references.)

1. Hugo M. Santos, Luís B. Carvalho, Carlos Lodeiro, Gonçalo Martins, Inês L. Gomes, Wilson D.T. Antunes, Vanessa Correia, Maria M. Almeida-Santos, Helena Rebelo-de-Andrade, António P.A. Matos, J.L. Capelo. How to dissect viral infections and their interplay with the host-proteome by immunoaffinity and mass spectrometry: A tutorial, Microchemical Journal, 2023. 186, article 108323. https://doi.org/10.1016/j.microc.2022.108323

2. Pestana, G.F., Carvalho, L.M., Gouveia-Carvalho, J., Antunes, W. (2022). Digital Chain of Custody for CBRNE Events: Custody Transfer Governance. In: Rocha, A., Adeli, H., Dzemyda, G., Moreira, F. (eds) Information Systems and Technologies. WorldCIST 2022. Lecture Notes in Networks and Systems, vol 469. Springer, Cham. https://doi.org/10.1007/978-3-031-04819-7_30

5. Briefly describe the biological defence work carried out at the facility, including type(s) of micro-organisms[30] and/or toxins studied, as well as outdoor studies of biological aerosols.

The work carried out is related to the detection, characterization and decontamination techniques in bacteria.

Confidence-Building Measure "E"

Declaration of legislation, regulations and other measures

At the Third Review Conference the States parties agreed to implement the following, later amended by the Seventh Review Conference:

As an indication of the measures which they have taken to implement the Convention, States parties shall declare whether they have legislation, regulations or other measures:

(a) To prohibit and prevent the development, production, stockpiling, acquisition or retention of the agents, toxins, weapons, equipment and means of delivery specified in Article I of the Convention, within their territory or anywhere under their jurisdiction or under their control anywhere;

(b) In relation to the export or import of micro-organisms pathogenic to man, animals and plants or of toxins in accordance with the Convention;

(c) In relation to biosafety and biosecurity.

States parties shall complete the attached form (Form E) and shall be prepared to submit copies of the legislation or regulations, or written details of other measures on request to the Implementation Support Unit (ISU) within the United Nations Office for Disarmament Affairs or to an individual State party. On an annual basis States parties shall indicate, also on the attached form, whether or not there has been any amendment to their legislation, regulations or other measures.

Form E

Declaration of legislation, regulations and other measures

Relating to	Legislation	Regulations	Other measures[31]	Amended since last year
(a) Development, production stockpiling, acquisition or retention of microbial or other biological agents, or				**No**

[30] Including viruses and prions.
[31] Including guidelines.

toxins, weapons, equipment and means of delivery specified in Article I		
(b) Exports of micro-organisms[32] and toxins		**No**
(c) Imports of micro-organisms[11] and toxins		**No**
(d) Biosafety[33] and biosecurity[34]	**Yes**[35]	**Yes**

[32] Micro-organisms pathogenic to man, animals and plants in accordance with the Convention.

[33] In accordance with the latest version of the WHO Laboratory Biosafety Manual or equivalent national or international guidance.

[34] In accordance with the latest version of the WHO Laboratory Biosecurity Guidance or equivalent national or international guidance.

[35] Portuguese Standard NP ISO 35001:2019 Biorisk management for laboratories and other related organizations

6. INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA ANTÓNIO XAVIER, UNIVERSIDADE NOVA DE LISBOA (INSTITUTE OF CHEMICAL AND BIOLOGICAL TECHNOLOGY – NEW UNIVERSITY OF LISBON) – (ITQB NOVA)

Form A, part 1 (i)

Exchange of data on research centres and laboratories[36]

1.	Name(s) of facility[37]	**Instituto de Tecnologia Química e Biológica António Xavier (ITQB – NOVA)**
2.	Responsible public or private organization or company	**Universidade NOVA de Lisboa (Public Institution)**
3.	Location and postal address	**Avenida da República, 2780 – 157 Oeiras.**

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

All R&D activities are supported by Fundação para a Ciência e Tecnologia (under responsibility of Ministry for Science, Technology and Higher Education), the European Commission or other national and international science funding agencies. None of the projects currently developed at ITQB NOVA is supported by the Ministry of Defense.

5. Number of maximum containment units[38] within the research centre and/or laboratory, with an indication of their respective size (m^2)

ITQB – NOVA does not have any BSL-4 Laboratories (none).

6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

Scientific research at ITQB – NOVA is mostly dedicated to the characterization of microorganisms, metabolomics, proteomics and microorganism-host relationships with plants, animals and human.

---

[36] The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.

[37] For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".

[38] In accordance with the latest edition of the WHO Laboratory Biosafety Manual, or equivalent.

Form A, part 1 (ii)

If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents[39] on a State Party's territory:

Biosafety level 3[40]	**No**
Biosafety level 2[41] (if applicable)	**Yes**

Any additional relevant information as appropriate:

_____

_____

_____

[39] Microorganisms pathogenic to humans and/or animals

[40] In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

[41] In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

7. Autoridade Tributária e Aduaneira (AT) – Direção de Serviços de Licenciamento (DSL) / Ministério das Finanças (Tax and Customs Authority – Ministry of Finance)

Confidence-Building Measure "E"

Declaration of legislation, regulations and other measures

At the Third Review Conference the States parties agreed to implement the following, later amended by the Seventh Review Conference:

As an indication of the measures which they have taken to implement the Convention, States parties shall declare whether they have legislation, regulations or other measures:

(a) To prohibit and prevent the development, production, stockpiling, acquisition or retention of the agents, toxins, weapons, equipment and means of delivery specified in Article I of the Convention, within their territory or anywhere under their jurisdiction or under their control anywhere;

(b) In relation to the export or import of micro-organisms pathogenic to man, animals and plants or of toxins in accordance with the Convention;

(c) In relation to biosafety and biosecurity.

States parties shall complete the attached form (Form E) and shall be prepared to submit copies of the legislation or regulations, or written details of other measures on request to the Implementation Support Unit (ISU) within the United Nations Office for Disarmament Affairs or to an individual State party. On an annual basis States parties shall indicate, also on the attached form, whether or not there has been any amendment to their legislation, regulations or other measures.

Form E

Declaration of legislation, regulations and other measures

Relating to	Legislation	Regulations	Other measures[42]	Amended since last year
(a) Development, production stockpiling, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I	**Yes**	**Yes**	**No**	**No**
(b) Exports of micro-organisms[43] and toxins	**Yes**	**Yes**	**No**	**No**
(c) Imports of micro-organisms[11] and toxins	Yes/No	Yes/No	Yes/No	Yes/No
(d) Biosafety[44] and biosecurity[45]	Yes/No	Yes/No	Yes/No	Yes/No

---

8. Instituto de Higiene e Medicina Tropical – Universidade Nova de Lisboa (Hygiene and Tropical Medicine Institute – New University of Lisbon) – (IHMT)

Confidence-Building Measure "A"

Part 1 Exchange of data on research centers and laboratories

At the Third Review Conference it was agreed that States Parties continue to implement the following:

"Exchange of data, including name, location, scope and general description of activities, on research centres and laboratories that meet very high national or international safety standards established for handling, for permitted purposes, biological materials that pose a

[42] Including guidelines.
[43] Micro-organisms pathogenic to man, animals and plants in accordance with the Convention.
[44] In accordance with the latest version of the WHO Laboratory Biosafety Manual or equivalent national or international guidance.
[45] In accordance with the latest version of the WHO Laboratory Biosecurity Guidance or equivalent national or international guidance.

high individual and community risk or specialize in permitted biological activities directly related to the Convention."

Modalities

The Third Review Conference agreed on the following, later amended by the Seventh Review Conference:

Data should be provided by States Parties on each facility, within their territory or under their jurisdiction or control anywhere, which has any maximum containment laboratories meeting those criteria for such maximum containment laboratories as specified in the latest edition of the WHO Laboratory Biosafety Manual and/or OIE[46] Terrestrial Manual or other equivalent guidelines adopted by relevant international organisations, such as those designated as biosafety level 4 (BL4, BSL4 or P4) or equivalent standards.

States Parties that do not possess a facility meeting criteria for such maximum containment should continue to Form A, part 1 (ii).

Form A, part 1 (i)

Exchange of data on research centers and laboratories[47]

1. Name(s) of facility[48] _____

2. Responsible public or private organization or company _____

3. Location and postal address _____

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

_____

5. Number of maximum containment units within the research center and/or laboratory, with an indication of their respective size (m2)

_____

6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

_____

[46] World Organization for Animal Health

[47] The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.

[48] For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".

Form A, part 1 (ii)

If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents[49] on a State Party's territory:

Biosafety level 3[50]	**Yes**
Biosafety level 2[51] (if applicable)	**Yes**

Any additional relevant information as appropriate:

The Institute of Hygiene and Tropical Medicine has

- The Mycobacteriology BSL3 laboratory supports research, educational and diagnostic activities in the field of Medical Mycobacteriology, comprises two rooms and is used for work with antibiotic-resistant Mycobacterium tuberculosis and non-tuberculous mycobacteria.

- The In Vivo Arthropod Security Facility (VIASEF) is an infrastructure, which offers the possibility of implementing studies on a wide range of arthropods and arthropod-transmitted pathogens. The VIASEF comprises arthropod containment level 3 (ACL-3), ACL-2/3 insectaries and associated laboratories (including a BSL-3 lab). The VIASEF is member of the Portuguese roadmap of research infra -structures.

The Institute of Hygiene and Tropical Medicine belongs to the Portuguese National Biosafety Network - Lab-PTBioNet.

Part 2 Exchange of information on national biological defence research and development programmes

At the Third Review Conference it was agreed that States Parties are to implement the following:

In the interest of increasing the transparency of national research and development programmes on biological defence, the States Parties will declare whether or not they conduct such programmes. States Parties agreed to provide, annually, detailed information on their biological defence research and development programmes including summaries of the objectives and costs of effort performed by contractors and in other facilities. If no biological defence research and development programme is being conducted, a null report will be provided.

[49] Microorganisms pathogenic to humans and/or animals

[50] In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

[51] In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

States Parties will make declarations in accordance with the attached forms, which require the following information:

(1) The objective and summary of the research and development activities under way indicating whether work is conducted in the following areas: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research;

(2) Whether contractor or other non-defence facilities are utilized and the total funding provided to that portion of the programme;

(3) The organizational structure of the programme and its reporting relationships; and

(4) The following information concerning the defence and other governmental facilities in which the biological defence research and development programme is concentrated;

(a) location;

(b) the floor areas (sqM) of the facilities including that dedicated to each of BL2, BL3 and BL4 level laboratories;

(c) the total number of staff employed, including those contracted full time for more than six months;

(d) numbers of staff reported in (c) by the following categories: civilian, military, scientists, technicians, engineers, support and administrative staff;

(e) a list of the scientific disciplines of the scientific/engineering staff;

(f) the source and funding levels in the following three areas: research, development, and test and evaluation; and

(g) the policy regarding publication and a list of publicly-available papers and reports.

Form A, part 2 (i)

National biological defence research and development programmes Declaration

Are there any national programmes to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such programmes would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

No

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of each programme.

9. INFARMED - Autoridade Nacional do Medicamento e Produtos de Saúde, I.P. (National Authority of Medicines and Health Products, I.P.)

Confidence-Building Measure "G"

Declaration of vaccine production facilities

To further increase the transparency of biological research and development related to the Convention and to broaden scientific and technical knowledge as agreed in Article X, each State party will declare all facilities, both governmental and non-governmental, within its territory or under its jurisdiction or control anywhere, producing vaccines licensed by the State party for the protection of humans. Information shall be provided on Form G attached.

Form G

Declaration of vaccine production facilities

1. Name of facility: **(In Portugal there are no vaccines production)**
2. Location (mailing address):
3. General description of the types of diseases covered:

---

10. Escola de Medicina – Universidade do Minho (Medicine School – Minho University)

Confidence-Building Measure "A"

Part 1 Exchange of data on research centres and laboratories

At the Third Review Conference it was agreed that States Parties continue to implement the following:

"Exchange of data, including name, location, scope and general description of activities, on research centres and laboratories that meet very high national or international safety standards established for handling, for permitted purposes, biological materials that pose a high individual and community risk or specialize in permitted biological activities directly related to the Convention."

Modalities

The Third Review Conference agreed on the following, later amended by the Seventh Review Conference:

Data should be provided by States Parties on each facility, within their territory or under their jurisdiction or control anywhere, which has any maximum containment laboratories meeting those criteria for such maximum containment laboratories as specified in the latest edition of the WHO[52] Laboratory Biosafety Manual and/or OIE[53] Terrestrial Manual or other equivalent guidelines adopted by relevant international organisations, such as those designated as biosafety level 4 (BL4, BSL4 or P4) or equivalent standards.

States Parties that do not possess a facility meeting criteria for such maximum containment should continue to Form A, part 1 (ii).

Form A, part 1 (i)

Exchange of data on research centres and laboratories[54]

1.	Name(s) of facility[55]	**Life and Health Sciences Research Institute**
2.	Responsible public or private organization or company	**University of Minho (Public)**
3.	Location and postal address	**School of Health Sciences, Campus de Gualtar University of Minho, 4710-057 Braga.**

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

All R&D activities are supported by Fundação para a Ciência e a Tecnologia (FCT), la Caixa Foundation, Infect-ERA, Gilead Sciences, Institut Merieux, Fundação Calouste Gulbenkian e Centro Clínico Académico – Braga, Associação (2CA-Braga).

5. Number of maximum containment units[56] within the research centre and/or laboratory, with an indication of their respective size (m^2)

No BSL-4 laboratories

6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

R&D projects on microbiological and immunological aspects of infectious diseases (risk group 1, 2, and 3)

[52] World Health Organization
[53] World Organization for Animal Health
[54] The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
[55] For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".
[56] In accordance with the latest edition of the WHO Laboratory Biosafety Manual, or equivalent.

Form A, part 1 (ii)

If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents[57] on a State Party's territory:

Biosafety level 3[58]	**yes**
Biosafety level 2[59] (if applicable)	**yes**

Any additional relevant information as appropriate:

BSL2: 50.4 m^2

BSL3: 76.8 m^2

Confidence-Building Measure "E"

Declaration of legislation, regulations and other measures

At the Third Review Conference the States parties agreed to implement the following, later amended by the Seventh Review Conference:
As an indication of the measures which they have taken to implement the Convention, States parties shall declare whether they have legislation, regulations or other measures:

(a) To prohibit and prevent the development, production, stockpiling, acquisition or retention of the agents, toxins, weapons, equipment and means of delivery specified in Article I of the Convention, within their territory or anywhere under their jurisdiction or under their control anywhere;

(b) In relation to the export or import of micro-organisms pathogenic to man, animals and plants or of toxins in accordance with the Convention;

(c) In relation to biosafety and biosecurity.

States parties shall complete the attached form (Form E) and shall be prepared to submit copies of the legislation or regulations, or written details of other measures on request to the Implementation Support Unit (ISU) within the United Nations Office for Disarmament Affairs or to an individual State party. On an annual basis States parties shall indicate, also on the attached form, whether or not there has been any amendment to their legislation, regulations or other measures.

[57] Microorganisms pathogenic to humans and/or animals

[58] In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

[59] In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

Form E

Declaration of legislation, regulations and other measures

Relating to	Legislation	Regulations	Other measures[60]	Amended since last year
(a) Development, production stockpiling, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I	**Yes**	**Yes**	**Yes**	**No**
(b) Exports of micro-organisms[61] and toxins	**Yes**	**Yes**	**Yes**	**No**
(c) Imports of micro-organisms[11] and toxins	**Yes**	**Yes**	**Yes**	**No**
(d) Biosafety[62] and biosecurity	**Yes**	**Yes**	**Yes**	**No**

[60] Including guidelines.
[61] Micro-organisms pathogenic to man, animals and plants in accordance with the Convention.
[62] In accordance with the latest version of the WHO Laboratory Biosafety Manual or equivalent national